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Abstract
Ollier disease and Maffucci syndrome are non-hereditary skeletal disorders characterized by
multiple enchondromas (Ollier disease) combined with spindle cell hemangiomas (Maffucci
syndrome). We report somatic heterozygous IDH1 (R132C and R132H) or IDH2 (R172S)
mutations in 87% of enchondromas, benign cartilage tumors, and in 70% of spindle cell
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hemangiomas, benign vascular lesions. In total, 35 of 43 (81%) patients with Ollier disease and 10
of 13 (77%) patients with Maffucci syndrome carried IDH1 (98%) or IDH2 (2%) mutations in
their tumors. Fourteen of sixteen patients displayed identical mutations in separate lesions.
Immunohistochemistry for mutant R132H IDH1 protein suggested intraneoplastic and somatic
mosaicism. IDH1 mutations in cartilage tumors are associated with hypermethylation and
downregulation of expression of several genes. Mutations were also found in 40% of solitary
central cartilaginous tumors and in four chondrosarcoma cell lines, enabling functional studies to
assess the role of IDH1 and IDH2 mutations in tumor formation.
Enchondroma is a benign cartilage forming tumor within the medullary cavity of the
bone 1-3. Patients with enchondromatosis syndrome, which encompasses seven major
subtypes, develop multiple enchondromas. Most common are non-hereditary Ollier disease
(subtype I) and Maffucci syndrome (subtype II), the latter distinguished by spindle cell
hemangioma in addition to multiple enchondromas 1, 3. Malignant transformation of
enchondromas towards chondrosarcomas occurs in >30% of the patients 3, 4.
Genome-wide screens have not identified a causative gene 5-9. These patients have an
increased incidence of gliomas 3, 10 and juvenile granulosa cell tumors 3, 11-13. IDH1 and,
more rarely IDH2 mutations in gliomas 14, 15, 16 and GNAS activating mutations in juvenile
granulosa cell tumors 17 have been reported. Interestingly, IDH1 and IDH2 mutations were
recently reported in solitary central and periosteal enchondromas and chondrosarcomas,
including few tumors from patients with enchondromatosis 18. The possibility of GNAS
mutations in enchondromas and chondrosarcomas has not been explored.
We therefore assessed whether IDH1, IDH2, or GNAS mutations may cause enchondroma
and spindle cell hemangioma formation in Ollier disease and Maffucci syndrome. Sequence
analysis of hotspot positions using lesional tissue from 43 patients with Ollier disease
revealed that heterozygous R132C IDH1 (c.394C>T), R132H IDH1 (c.395G>A) or R172S
IDH2 (c.516G>C) (Human Genome Variation Society) mutations were present in 33
patients (78%) (Supplementary Fig.1a-c). In Maffucci syndrome, 7 out of 13 patients (54%)
carried R132C IDH1 mutations. Mutations were absent in DNA from patients' blood, muscle
or saliva (Supplementary Fig.1b). Mutations in GNAS were absent.
An additional 8 tumors demonstrated sub-threshold peaks at the position where R132C or
R132H IDH1 mutations can be expected, suggesting that the mutant allele might be present
in a small subpopulation of the tumor cells at the limits or below the detection level of
Sanger sequencing. We therefore performed a hydrolysis probes assay, capable of detecting
as low as 1% of mutant allele, for the detection of R132C and R132H IDH1 mutations 19, 20.
Mutations were confirmed in 7 of 8 tumors (Supplementary Fig.1d-g), while from 1 tumor
DNA was no longer available. Thus, in total 35 out of 43 (81%) and 10 of 13 (77%) patients
with Ollier disease and Maffucci syndrome, respectively, showed IDH1 or IDH2 mutations
(Fig.1a, Table 1, and Supplementary Table 1). Frequency of mutations in tumors is shown in
Fig.1b.
Other subtypes of enchondromatosis syndrome are known to be caused by mutations in
PTPN11 (metachondromatosis) 21, 22, ACP5 (spondyloenchondrodysplasia) 23, 24 and
PTHLH duplication (symmetrical enchondromatosis) 25. Mutations in PTH1R, involved in
enchondral bone formation, are found in ∼ 8% of patients with Ollier disease, but not in
patients with Maffucci syndrome 5-7. Previously, our patients were reported negative for
PTPN11 mutations 22. Here we did not detect PTH1R mutations in a screen of 35 patients. A
custom-made Agilent tiling array (Supplementary Table 2) analysis did not find evidence of
losses or gains of IDH1, IDH2, PTHLH, PTPN11, PTH1R, EXT1, EXT2 and ACP5. Thus,
even though patients with enchondromatosis syndromes demonstrate overlapping clinical
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features, they appear to be genetically discrete entities, with the exception of Ollier disease
and Maffucci syndrome, which we have now shown to contain IDH1 or IDH2 mutations.
Since these disorders are not inherited and the enchondromas are often unilateral, we further
hypothesized that mutations may occur in a somatic mosaic fashion. Fourteen of sixteen
patients (88%) possessed identical mutations, including rare variants, in more than one
tumor (Supplementary Table 1). We additionally used immunohistochemistry to determine
the distribution of the R132H IDH1 mutant protein. Of 68 tumors from patients with Ollier
disease, 17 tumors (25%) showed mutant protein expression while 51 (75%) tumors were
negative (Table 2, Fig.2). We observed a mixture of cells without (wild-type) and with
expression of R132H IDH1 mutant protein (of the same histologic type, i.e., not including
entrapped elements and supporting elements), which we refer to as intraneoplastic
mosaicism (Fig.2a and b). The percentage of positive tumor cells ranged from 50% to 95%.
Intraneoplastic mosaicism is also described for other benign bone tumors. In fibrous
dysplasia, experimental evidence showed that both normal and GNAS mutated cells were
needed to develop fibrous dysplasia-like lesions 26. Also, in osteochondromas, benign
cartilaginous tumors arising at the surface of the bone that are caused by mutations in EXT1
or EXT2, a mixture of EXT wild-type and EXT mutated cells was observed 27-30. EXT is
involved in heparan sulphate biosynthesis, and it is hypothesized that EXT mutated cells that
are deficient in heparan sulphate, need heparan sulphate from neighboring cells for cellular
signaling and survival 31, 32.
We additionally studied the surrounding normal tissue of Ollier related and solitary mutated
tumors and surprisingly, a very low frequency (on average <1%) of mutant protein was
observed in osteoblasts, osteocytes, adipocytes and fibroblasts (Fig. 2d and e). Hydrolysis
probes assay could be performed on DNA isolated from one normal bone of patient with
Ollier disease, which was negative. Mutant R132H IDH1 protein was absent in 12 bones
resected for reasons other than chondrosarcoma, normal growth plates and articular cartilage
(Table 2). Therefore, our current data support somatic mosaicism, similar to somatic mosaic
GNAS mutations causing polyostotic fibrous dysplasia 33, 34. Unfortunately, the nature of
the material (decalcified paraffin-embedded bone tissue) and the occurrence of the mutation
in single scattered cells do not allow verification using other techniques. However, the
R132H IDH1 antibody was shown to be highly reliable in glioma diagnosis 35 and correlated
well with sequence analysis in our series.
Twelve tumors were negative for IDH1 or IDH2 hotspot mutations. For 5 of these, all exons
were sequenced and no mutations were identified. This was not surprising because only
R132 IDH1 and R172 IDH2 mutations have been identified in other IDH-associated tumors.
It is possible that because of intralesional mosaicism, only small sub-fraction of tumor cells
contain the IDH1 or IDH2 hotspot mutations, which may be below the detection level of the
techniques used. Alternatively, mutations in other genes such as TET2, which is mutually
exclusive with IDH1 or IDH2 mutations in cases of acute myeloid leukemia 36, might be
involved 18, 37.
Recently, point mutations in IDH1 or IDH2 were reported in 56% of solitary central and
periosteal cartilaginous tumors 18, and the data within our control group are in concordance
with these findings. In total 40 of 101 (40%) solitary central tumors, 7 of 13 (54%)
dedifferentiated chondrosarcomas and 3 of 3 periosteal chondrosarcomas displayed IDH1 or
IDH2 mutations (Fig.1b, Table 1). In 6 additional tumors, the mutant allele seemed to be
present below the detection level of Sanger sequencing. IDH1 or IDH2 mutations were
absent in other subtypes of cartilaginous tumors, in angiosarcomas (Fig.1b) and in patients'
blood. Immunohistochemistry for the R132H IDH1 mutant protein on tissue microarrays
(TMA) containing cartilaginous and vascular tumors confirmed that mutant protein
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expression was restricted to central, dedifferentiated and periosteal cartilage tumors, while
all other tumors were negative (Table 2). Interestingly, four of eight solitary
chondrosarcoma cell lines carry different types of mutations in IDH1 or IDH2 (Table 3). To
the best of our knowledge, no cell lines with IDH1 or IDH2 mutations are currently
available. IDH1 or IDH2 mutations were more frequently found in solitary central tumors
located in hands and feet (11 out of 14) versus those located in long and flat bones (28 out of
84) (p=0.006, Pearson Chi-Square test), which was also reported previously 18. This
correlation was absent in Ollier disease (20 out of 22 versus 28 out of 34, p=0.5, Pearson
Chi-Square test). While in gliomas, mutations in IDH1 or IDH2 predict a favorable
outcome 38, we found no significant prognostic value of these mutations in solitary central
cartilaginous tumors using multivariate analysis (Cox Regression, p-value = 0.3).
IDH1 or IDH2 mutations have also been reported at lower frequencies in various other
tumors such as acute myeloid leukemia (AML) (8%) 39, 40, prostate cancer (2.7%) 40, 41,
paragangliomas (0.7%) 40, 42 and thyroid carcinoma (16%) 43. The high mutation frequency
in enchondromas and the fact that they are early events suggest a causal rather than a
bystander role for IDH1 or IDH2 mutations in tumorigenesis in Ollier disease and Maffucci
syndrome. In gliomas, mutant IDH1 or IDH2 leads to gain of function by producing 2-
hydroxyglutarate (2HG), a structural analogue of α-KG, and by ultimately reducing α-KG
production 44. In AML, it was demonstrated that mutant IDH protein results in DNA
hypermethylation and impairment of hematopoietic differentiation 36, and in gliomas the
presence of an IDH1 mutation is strongly associated with hypermethylation 45. Therefore,
we used Illumina HumanMethylation27 BeadChip (Illumina Inc., CA) to assess a possible
difference in methylation between enchondromas with (n = 8) and without (n = 4) IDH1
mutations detectable at Sanger sequencing. Unsupervised clustering based on the 2000 most
variable CpG methylation sites resulted in 2 subgroups (Fig.3). One of these subgroups
showed an overall higher methylation at the examined CpG sites and is therefore similar to
the CpG island methylator phenotype (CIMP) as described in colon carcinoma and
glioblastoma 45, 46. All but one enchondroma with an IDH1 mutation were CIMP+.
Supervised clustering analysis indicated that 797 CpG sites are differentially methylated by
more than 20% (at p<0.05) between enchondromas with and without IDH1 mutations.
Interestingly 710 (89.1%) of these differentially methylated CpG sites were methylated in
the enchondromas with IDH1 mutations (Supplementary Table 3). These results are in line
with the hypothesis that IDH1 mutations induce methylation and thus contribute to the
CIMP phenotype 36.
To assess the effect of IDH1 or IDH2 mutations on mRNA expression levels in cartilaginous
tumors, we performed whole-genome gene expression analysis using Illumina Human-6 v3
array (Illumina Inc., CA). High quality mRNA was available for only three tumors in which
mutation was negative (n=1) or below the threshold of Sanger sequencing (thus possibly
carrying a low percentage of mutated cells)(n=2). Comparison with 18 tumors with clearly
detectable IDH1 or IDH2 mutations using LIMMA analysis showed 36 differentially
expressed probes encoding for 33 genes (Supplementary Table 4). 32 of 33 genes were
down regulated in tumor samples with an IDH1 or IDH2 mutation. There was no overlap
between the affected genes found in methylation and expression analysis.
One of the most differentially methylated genes was DLX5. There was a trend for
downregulation of DLX5 but this was not significant in Ollier enchondromas versus controls
(adj. p-value = 0.3, Supplementary Fig.2). The controls consisted of 2 growth plates and 4
articular/rib cartilage samples. The homeodomain transcription factor DLX5 is a cell
autonomous positive regulator of chondrocyte maturation during endochondral ossification,
promoting the conversion of immature proliferating chondrocytes into hypertrophic
chondrocytes 47, 48 DLX5 also induces expression of Runx2 and osterix, promoting
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osteogenic differentiation 49, 50. Future studies should reveal whether down regulation of
DLX5 through methylation as a consequence of IDH1 mutation delays hypertrophic
differentiation of chondrocytes and inhibits subsequent osteogenic differentiation, thereby
leaving clusters of proliferating chondrocytes behind.
In summary, we report a large multi-institutional series demonstrating somatic heterozygous
IDH1 or, rarely, IDH2 point mutations in tumor tissues of 81% of patients with Ollier
disease and 77% of patients with Maffucci syndrome, and provide evidence for
intraneoplastic and somatic mosaicism. Future studies using deep sequencing approaches
should reveal whether the percentage of patients carrying somatic mosaic IDH1 or IDH2
mutations is even higher than that detected in our series, or whether other genes are
involved. We show the IDH1 mutation to be associated with hypermethylation and
downregulation of several genes. Future studies should demonstrate a causal effect and it
will be of great interest to assess how this dysregulation leads to enchondroma and spindle
cell hemangioma formation. Finally, this is the first report of four chondrosarcoma cell lines
carrying IDH1 or IDH2 mutations, providing good in vitro models for functional studies to
dissect the role of IDH1 and IDH2 in Ollier disease and Maffucci syndrome, but also in
tumorigenesis in general.
Data Deposition
MIAME-compliant data of tiling arrays, expression arrays and methylation arrays have been
deposited in the GEO database (www.ncbi.nlm.nih.gov/geo/, accession number GSE30844).
Materials and Methods
Patients and Clinical Specimens
Fresh frozen tumor tissues (n = 60) of 44 patients with multiple cartilage tumors (36 patients
with Ollier disease and 8 patients with Maffucci syndrome) (Table 1, Supplementary Table
1) were collected from EuroBoNet consortium (http://www.eurobonet.eu) 8 and the
Laboratory of Human Molecular Genetics at the de Duve Institute, UCL (Brussels,
Belgium). In addition, paraffin embedded tumor tissues (n = 15) from 12 patients were
obtained from the files of the Children's Hospital (Boston, USA). Samples were handled
according to the ethical guidelines of the host institution. All samples were coded and the
ethical guidelines “Code for Proper Secondary Use of Human Tissue in The Netherlands”
(Dutch Federation of Medical Scientific Societies) were followed in all procedures.
Chondrosarcoma samples were graded according to Evans et al 56. Normal DNA derived
from saliva, blood or muscle was available from 12 patients with Ollier disease. Patients'
ages were documented at the time of operation. Demographic and survival data were
obtained from the host institutions' patient records.
For comparison with other cartilage tumors, we included DNA from solitary enchondromas
(n =9), solitary central chondrosarcomas (n=92), central dedifferentiated chondrosarcomas
(n=13), periosteal chondrosarcomas (n=3), 37 peripheral cartilaginous tumors [solitary
osteochondroma (n = 11), peripheral chondrosarcomas (n=20), multiple osteochondromas
(n=6)], as well as 9 chondromyxoid fibromas, 7 chondroblastomas, and 2 osteochondroma-
like lesions of metachondromatosis. Matching blood-derived DNA was also available from
24 cases as controls. Additionally, we included DNA from angiosarcomas (n = 14) since
patients with Maffucci syndrome have central cartilage tumors combined with vascular
tumors. The angiosarcomas, chondromyxoid fibromas and chondroblastomas were analyzed
for IDH1 mutations only. Thus, in total we analyzed 261 tumors from 242 patients.
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DNA extraction and Mutation Analysis
Genomic DNA from frozen tumors containing at least 80% of tumors cells, as estimated on
haematoxylin and eosin-stained frozen sections, from blood and from saliva was isolated as
described earlier 8. DNA from paraffin embedded tissue was isolated after micro dissection
as previously described 8. For cell lines and primary cultures, DNA was isolated from cell
pellets using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI),
according to the manufacturer's instructions.
PCR amplification was performed on IDH1 exon 4 for all the samples. IDH2 exon 4 was
amplified in samples without IDH1 mutation and GNAS exon 8 was studied in samples
without IDH1 and IDH2 mutations. To correlate with possible PTH1R mutations we also
amplified PTH1R exon 4 for G121E and A122T, exon 5 for R150C and exon 9 for R255H
using DNA from 35 patients with Ollier disease and Maffucci syndrome. PCR was
performed in 25μl reactions using 10ng DNA, 12.5 μl of iQ SYBR green Supermix (Bio-
Rad, CA) and 10 pmol M13 tailed primers (Supplementary Table 5). The PCR was carried
out in a CFX 96 ™ Real-Time PCR detection system (Bio-Rad, CA) at an initial
denaturation step of 5 min 95°C followed by 40 cycles of 10 sec 95 °C, 10 sec 60 °C and 10
sec 72 °C. After a final elongation step of 10 min at 72 °C, a melt curve was obtained to
check for the quality of the PCR products. PCR products were purified using the Qiagen
MinElute ™ 96 UF PCR Purification kit (Qiagen) system and finally eluted in 25μl sterile
water. PCR amplimers were sequenced by a commercial party using standard forward and
reverse M13 primers (Macrogen Inc. Europe, Amsterdam). The sequence trace files were
analyzed with Mutation Surveyor™ DNA variant software (version 3.97 SoftGenetics, PA).
To validate the R132C and R132H IDH1 mutations, we designed hydrolysis probes
(Supplementary Table 6) assays using the Custom Taqman® Assay Design Tool (Applied
Biosystems, Nieuwerkerk a/d Ijssel, NL). Assays were performed on 144 samples including
tumors related to Ollier disease, Maffucci syndrome, solitary cartilaginous tumors,
chondrosarcoma cell-lines, blood from Ollier patients as well as negative controls (healthy
donor DNA) together with no template controls. qPCR was performed in 10 μL reactions as
described earlier 57 in a CFX384™ Real-Time PCR Detection System (Bio-Rad,
Veenendaal, NL) for 10 minutes at 95 °C and 40 cycles of 10 seconds at 92 °C and 30
seconds at 60 °C. The quantification cycle (Cq) was used for quality assessment and samples
with Cq>35 for the wild-type allele were considered as DNA negative. The threshold for the
mutant allele R132C IDH1 (c.394C>T) or R132H IDH1 (c.395G>A) was set after
subtracting the highest background signal from the negative controls.
There was sufficient DNA left to perform sequence analysis of all exons of IDH1 and IDH2
from 5 of 12 tumors without mutation. One IDH1 mutated tumor was also sequenced. PCR
was performed as mentioned above for exon 4 and primer sequences are listed in
supplementary Table 5.
Tiling Resolution Targeted Oligonucleotide Arrays
Custom designed Agilent tiling oligonucleotide array CGH (Agilent, Amstelveen, The
Netherlands) containing 15,000 probes with a tiling coverage of genes involved in the
different types of enchondromatosis syndromes (IDH1, IDH2, ACP5, PTH1R, PTPN11,
EXT1, EXT2 and PTHLH) (Supplementary Table 2) was performed to detect possible
small, intragenic losses and gains in these genes. In total 16 enchondromas and
chondrosarcomas of patients with Ollier disease and Maffucci syndrome, with (n=14) and
without (n=2) IDH1 or IDH2 mutations were selected. Labeling and hybridization of
genomic DNA from freshly frozen tumor and data processing were performed as described
earlier 58.
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Immunohistochemistry
To determine the protein expression of the R132H IDH1 mutant allele,
immunohistochemistry was performed as described earlier 8 using R132H IDH1 antibody
(1:200 dilution 5% in non-fat milk, citrate antigen retrieval, blocking for 30′ with 5% non-
fat milk) from Dianova (Hamburg, Germany). We used 403 tumors (Table 2) on 19 tissue
microarrays (TMA), for which details were published previously 8, 59-61. Additional cases
from Ollier disease and Maffucci syndrome were collected through EMSOS, and clinical
details for these patients are described separately 4. Glioma tissue with a known IDH1
mutation was used as a positive control and primary antibody was omitted as a negative
control. Only strong cytoplasmic staining combined with nuclear staining was considered a
positive result 35. To study possible mosaicism in the tumor and in surrounding normal
tissues, we selected resection specimens from tumors expressing R132H IDH1 mutant
protein (n = 7) and stained multiple tissue blocks from different areas. All except 9 tumors
of patients with Ollier disease that were used for mutation analysis were also included in the
TMA, and results were confirmed.
Statistical Analysis for Clinical Correlation
From 83 patients with solitary tumors, follow up data were available (range 2 to 335 months,
mean 115.23). To investigate the relation of IDH1 or IDH2 mutations with patients' clinical
features, multivariate survival analysis (Cox Regression) and cross-tabulations (Pearson
Chi-Square) were performed using SPSS version 16.0 (Chicago, Illinois, USA). Statistical
analysis was not performed for patients with Ollier disease because nearly all patients with
available follow up data had IDH1 or IDH2 mutations. All the p-values reported are two-
sided and p-values < 0.05 were considered to indicate statistical significance.
DNA Methylation Profiling
Total 12 samples which includes 8 enchondromas with IDH1 mutation (4 Ollier
enchondromas, 2 Maffucci enchondromas and 2 solitary enchondromas) and 4
enchondromas (1 Ollier enchondroma, 3 solitary enchondromas) without IDH1 or IDH2
mutations were used. Of these 4 enchondromas without IDH1 mutation, one had R132G
IDH1 mutated cells present in the subpopulation, below the threshold level of Sanger
sequencing. Bisulfite treatment was performed using EZ DNA Methylation™ Kit (Zymo
Research, Orange, CA). Bisulfite converted DNA was then hybridized to Illumina
HumanMethylation27 BeadChip (Illumina Inc., San Diego, CA) by following
manufacturer's instructions. Infinium Unsupervised clustering analysis was performed using
the Ward's clustering algorithm based on Euclidian distance. The 2000 most variable CpG
sites (excluding those on the X and Y chromosomes) were used in the clustering analysis.
Genome-wide gene expression analysis
A total of 21 tumors including 6 enchondromas and 10 chondrosarcomas (6 grade I, 4 grade
II) of Ollier disease and Maffucci syndrome as well as 1 solitary enchondroma and 4 solitary
chondrosarcomas grade II and 6 controls (2 growth plates, 4 normal cartilage) were used.
We determined differential expression between tumors with IDH1 or IDH2 mutations (n =
18) versus tumors without detectable IDH1or IDH2 mutation using Sanger sequencing
(n=3). Two of these demonstrated subthreshold peaks for R132G and R132C IDH1 mutation
suggesting a mutation in a minor subpopulation of tumor cells. Experimental procedures
using the Illumina Human-6 v3.0 Expression BeadChips were performed as described
previously 8, 62, 63. LIMMA analysis 64 was used to determine differential expression
between the groups. Probes with Benjamini and Hochberg false discovery rate-adjusted P-
values (adjP) < 0.05 and a log fold change (logFC) > 0.1 were considered to be significantly
differentially expressed.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Frequency of IDH1 and IDH2 mutations
a) Distribution of the different R132 IDH1 and R172 IDH2 mutations among the patients
with Ollier disease, Maffucci syndrome and solitary tumors. b) Frequency of somatic
heterozygous IDH (IDH1 and IDH2) mutations in tumors of patients with Ollier disease and
Maffucci syndrome, in comparison with different subtypes of solitary cartilaginous tumors
and angiosarcomas.
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Figure 2. Immunohistochemistry for R132H IDH1 mutant protein
a,b) Enchondroma (L1490) of patient with Ollier disease demonstrating strong cytoplasmic
and nuclear staining of R132H IDH1 mutant protein. Note the mixture of wild-type and
mutated cells indicating intraneoplastic mosaicism. Overall the percentage of positive tumor
cells ranged from 50% to 95%. Insets show vitality of the negative cells at higher
magnification. c) Grade II chondrosarcoma negative for R132H IDH1 mutant protein. d and
e) Enchondromas from patients with Ollier disease demonstrating occasional positive cells
in the surrounding normal bone. Some positive osteocytes (arrows) and osteoblasts
(arrowheads) are seen. T: tumor tissue. (Magnification 400×)
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Figure 3. CpG island Methylator Phenotype in enchondromas with IDH1 mutations
Heatmap depicting unsupervised clustering analysis based on the 2000 most variable CpG
sites of enchondromas with IDH1 mutations (orange, n = 8) and without IDH1 mutation
(gray, n=4). The level of DNA methylation (beta value) for each probe (columns) in each
sample (rows) is represented by color scale as shown in the picture ranging from 0 (0%
methylation, blue) to 1 (100% methylation, yellow). Asterisk indicates sample L2357 in
which the R132G IDH1 mutant allele was detected in a subpopulation of cells. However, the
mutation escaped detection at Sanger sequencing, and therefore the sample is labeled “wild-
type”.
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Table 2
Immunohistochemistry for R132H mutant protein expression
Total nr of tumors R132H positive
Ollier Disease
 Enchondroma 46 14/43*(32%)
 Chondrosarcoma grade I 22 3/17* (18%)
 Chondrosarcoma grade II 10 0/8*
Maffucci syndrome
 Enchondroma 9 0/9
 Spindle cell hemangioma 14 0/14
Solitary tumors
 Enchondroma 19 4/19 (21%)
 Central chondrosarcoma grade I 42 4/38* (10%)
 Central chondrosarcoma grade II 36 1/32* (3%)
 Central chondrosarcoma grade III 14 0/11*
 Central dedifferentiated chondrosarcoma 26 1/24* (4%)
 Periosteal chondrosarcoma 6 1/6 (17%)
 Solitary osteochondroma 20 0/17*
 Multiple osteochondroma 7 0/7
 Peripheral chondrosarcoma 45 0/35*
 Peripheral dedifferentiated chondrosarcoma 16 0/16
 Conventional hemangioma 3 0/3
 Hemangioendothelioma 2 0/2
 High grade angiosarcoma of bone 44 0/44
 High grade angiosarcoma of soft tissue 22 0/22
Controls
 Normal growth plate 3 0/3
 Articular cartilage 3 0/3
 Normal bone 12 0/12
*
not all tumors included were evaluable due to tissue loss on tissue microarray
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